HuidaGene Therapeutics

HuidaGene Therapeutics Announces Publication of the World’s First Guanine Base-Editor

by

SHANGHAI and CLINTON, N.J., May 18, 2023 /PRNewswire/ — HuidaGene Therapeutics (辉大基因; HuidaGene), a clinical-stage genome-editing company, today announced the online National Science Review published the comprehensive data from a study of the world’s first DNA base editor converting G-to-Y, glycosylase-based guanine base editor (gGBE). Company has filed an international patent application for this base … Read more

HuidaGene Therapeutics’ Novel DNA Gene-Editing System Cas12i Patent Granted by USPTO

by

SHANGHAI and CLINTON, N.J., May 16, 2023 /PRNewswire/ — HuidaGene Therapeutics (辉大基因; HuidaGene), a clinical-stage company focusing on developing gene editing tools and gene therapies, today announced that the United States Patent and Trademark Office (USPTO) has granted to the Company patent US11,649,444B1 with respect to its independently-developed DNA editing system, CRISPR-Cas12i (Cas12Max®), in just 9 … Read more